Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TAK-491

Known as: TAK 491, TAK491 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

azilsartan medoxomil

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Development, validation and application of the liquid chromatography tandem mass spectrometry method for simultaneous quantification of azilsartan medoxomil (TAK-491), azilsartan (TAK-536), and its 2…
Azilsartan medoxomil potassium salt (TAK-491) is an orally administered angiotensin II type 1 receptor blocker for the treatment… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
Absorption of TAK-491, a new angiotensin II receptor antagonist, in animals
The absorption process in animals of TAK-491, designed as ester-based prodrug with medoxomil moiety, was evaluated. In the plasma… Expand
2011
2011
The Angiotensin Receptor Blocker, Azilsartan Medoxomil (TAK-491), Suppresses Vascular Wall Expression of Plasminogen Activator Inhibitor Type-I Protein Potentially Facilitating the Stabilization of…
Increased expression of plasminogen activator inhibitor type-I (PAI-1) in vessel walls seems to accelerate atherosclerosis… Expand
Review
2011
Review
2011
Azilsartan medoxomil: a new Angiotensin receptor blocker.
BACKGROUND Azilsartan medoxomil is an angiotensin receptor blocker, approved on February 25, 2011 by the US Food and Drug… Expand
Review
2011
Review
2011
Azilsartan Medoxomil: A New Angiotensin II Receptor Antagonist for Treatment of Hypertension
Objective: To evaluate the efficacy, safety, and clinical role of azilsartan medoxomil, an angiotensin II receptor blocker (ARB… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
2011
2011
INHIBITION OF THE ANGIOTENSIN II TYPE-1 (AT-1) RECEPTOR BY THE ANGIOTENSIN RECEPTOR BLOCKER AZILSARTAN MEDOXOMIL (TAK-491) SUPPRESSES AORTIC EXPRESSION OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-I (PAI…
 
2010
2010
Additive Effect of TAK-491, a New Angiotensin Receptor Blocker, and Pioglitazone, in Reducing Myocardial Infarct Size
PurposeWe assessed the effects of TAK-491 (a newly designed potent and selective ARB) alone and in combination with pioglitazone… Expand
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE